STOCK TITAN

[8-K] Medtronic plc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated September 15, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC named as the representatives of the several underwriters. The filing also notes an embedded Cover Page Interactive Data File with the Inline XBRL document. The filing is signed on September 16, 2025 by Thierry Piéton, Executive Vice President and Chief Financial Officer.

The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.

Medtronic plc ha presentato un 8-K che divulga un Accordo di Underwriting datato September 15, 2025 tra Medtronic, Inc., Medtronic plc e Medtronic Global Holdings S.C.A., con Deutsche Bank AG, London Branch e Goldman Sachs & Co. LLC nominati come rappresentanti dei vari underwriters. Il deposito annota anche un Embedded Cover Page Interactive Data File con il documento Inline XBRL. Il deposito è firmato il September 16, 2025 da Thierry Piéton, Executive Vice President e Chief Financial Officer.

La notifica identifica l'esistenza e la data dell'accordo di sottoscrizione e i lead underwriters ma non divulga dimensione della transazione, termini o uso previsto dei proventi.

Medtronic plc presentó un 8-K que divulga un Acorde de Suscripción datado 15 de septiembre de 2025 entre Medtronic, Inc., Medtronic plc y Medtronic Global Holdings S.C.A., con Deutsche Bank AG, London Branch y Goldman Sachs & Co. LLC designados como representantes de los diversos suscriptores. El archivo también señala un Archivo de Datos Interactivos de la Portada de Cubierta incorporado con el documento Inline XBRL. El depósito está firmado el 16 de septiembre de 2025 por Thierry Piéton, Vicepresidente Ejecutivo y Director Financiero.

El aviso identifica la existencia y la fecha del acuerdo de suscripción y los suscriptores principales, pero no revela el tamaño de la transacción, los términos ni el uso previsto de los fondos.

Medtronic plc2025년 9월 15일자 인수계약을 포함한 8-K를 제출했고, 이는 Medtronic, Inc., Medtronic plc 및 Medtronic Global Holdings S.C.A. 간에 체결되었으며 Deutsche Bank AG, London BranchGoldman Sachs & Co. LLC가 여러 인수단 담당자로 지명되었습니다. 이 제출은 Inline XBRL 문서가 포함된 커버 페이지 인터랙티브 데이터 파일을 주목합니다. 이 제출은 September 16, 2025Thierry Piéton, 부사장 겸 최고재무책임자에 의해 서명되었습니다.

통지는 인수계약의 존재 여부와 날짜를 식별하지만, 거래 규모, 조건 또는 예상 자금 사용은 공개하지 않습니다.

Medtronic plc a déposé un 8-K divulguant un accord de souscription daté du 15 septembre 2025 entre Medtronic, Inc., Medtronic plc et Medtronic Global Holdings S.C.A., avec Deutsche Bank AG, London Branch et Goldman Sachs & Co. LLC désignés comme représentants des souscripteurs. Le dossier indique également un fichier de données interactives de couverture intégré au document Inline XBRL. Le dépôt est signé le 16 septembre 2025 par Thierry Piéton, vice-président exécutif et directeur financier.

L'avis identifie l'existence et la date de l'accord de souscription et les souscripteurs principaux mais ne révèle ni la taille de la transaction, ni les termes, ni l'utilisation prévue des fonds.

Medtronic plc reichte eine 8-K ein, die ein Underwriting Agreement dated September 15, 2025 zwischen Medtronic, Inc., Medtronic plc und Medtronic Global Holdings S.C.A. umfasst, wobei Deutsche Bank AG, London Branch und Goldman Sachs & Co. LLC als Vertreterinnen der jeweiligen Underwriter benannt sind. Die Einreichung vermerkt auch eine eingebettete Cover Page Interactive Data File mit dem Inline XBRL-Dokument. Die Einreichung ist am September 16, 2025 von Thierry Piéton, Executive Vice President und Chief Financial Officer, signiert.

Die Mitteilung identifiziert die Existenz und das Datum der Underwriting-Vereinbarung und die Lead Underwriters, offenbart jedoch weder die Transaktionsgröße, die Bedingungen noch die beabsichtigte Verwendung der Erlöse.

Medtronic plc قدمت ملف 8-K يكشف عن اتفاقية الاكتتاب المؤرخة 15 سبتمبر 2025 بين Medtronic, Inc. وMedtronic plc وMedtronic Global Holdings S.C.A., مع Deutsche Bank AG, London Branch وGoldman Sachs & Co. LLC مذكورين كنواب للكتّاب المستقلين. كما يشير الملف إلى وجود ملف بيانات مدمج على صفحة الغلاف التفاعلية مع مستند Inline XBRL. وهذا التقديم مُوقّع في 16 سبتمبر 2025 من قبل Thierry Piéton، نائب الرئيس التنفيذي ومدير القسم المالي.

وتشير الإخطار إلى وجود وتاريخ ترتيب الاكتتاب والكتّاب الرئيسيين، لكنها لا تكشف عن حجم الصفقة أو الشروط أو الاستخدام المقصود لعائدات.

Positive
  • Underwriting Agreement disclosed with specific effective date: September 15, 2025
  • Leading global banks named as representatives: Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC
  • Signed by CFO (Thierry Piéton), indicating authorized corporate disclosure
Negative
  • No offering size, pricing, or securities type disclosed, preventing assessment of dilution or proceeds
  • No stated use of proceeds or closing timeline, leaving investor impact unclear
  • Limited detail in the 8-K — additional filings will be required to evaluate material financial effects

Insights

TL;DR: An underwriting agreement was disclosed with major banks named, but no deal size or terms were provided.

The company reported an Underwriting Agreement dated September 15, 2025 and listed Deutsche Bank and Goldman Sachs as book‑running representatives. This confirms intent to engage capital markets intermediaries for a securities placement or offering process.

Key dependencies are the missing transaction details: without offering size, pricing, or structure, investors cannot assess dilution, proceeds, or timing. Watch for a follow‑up filing that provides the offering prospectus, size, pricing, or use of proceeds within the required SEC disclosure timeline.

TL;DR: The 8-K properly discloses the agreement and identifies signing authority, but is sparse on material terms.

The filing names the parties to the Underwriting Agreement and includes an Inline XBRL cover page; it is signed by the CFO on September 16, 2025. This satisfies basic Form 8‑K notice requirements for a material agreement disclosure.

Absent are any contractual terms, conditions precedent, or closing timelines; therefore compliance observers should look for subsequent filings such as a prospectus supplement or Form 424(b) that will contain material terms and pricing information.

Medtronic plc ha presentato un 8-K che divulga un Accordo di Underwriting datato September 15, 2025 tra Medtronic, Inc., Medtronic plc e Medtronic Global Holdings S.C.A., con Deutsche Bank AG, London Branch e Goldman Sachs & Co. LLC nominati come rappresentanti dei vari underwriters. Il deposito annota anche un Embedded Cover Page Interactive Data File con il documento Inline XBRL. Il deposito è firmato il September 16, 2025 da Thierry Piéton, Executive Vice President e Chief Financial Officer.

La notifica identifica l'esistenza e la data dell'accordo di sottoscrizione e i lead underwriters ma non divulga dimensione della transazione, termini o uso previsto dei proventi.

Medtronic plc presentó un 8-K que divulga un Acorde de Suscripción datado 15 de septiembre de 2025 entre Medtronic, Inc., Medtronic plc y Medtronic Global Holdings S.C.A., con Deutsche Bank AG, London Branch y Goldman Sachs & Co. LLC designados como representantes de los diversos suscriptores. El archivo también señala un Archivo de Datos Interactivos de la Portada de Cubierta incorporado con el documento Inline XBRL. El depósito está firmado el 16 de septiembre de 2025 por Thierry Piéton, Vicepresidente Ejecutivo y Director Financiero.

El aviso identifica la existencia y la fecha del acuerdo de suscripción y los suscriptores principales, pero no revela el tamaño de la transacción, los términos ni el uso previsto de los fondos.

Medtronic plc2025년 9월 15일자 인수계약을 포함한 8-K를 제출했고, 이는 Medtronic, Inc., Medtronic plc 및 Medtronic Global Holdings S.C.A. 간에 체결되었으며 Deutsche Bank AG, London BranchGoldman Sachs & Co. LLC가 여러 인수단 담당자로 지명되었습니다. 이 제출은 Inline XBRL 문서가 포함된 커버 페이지 인터랙티브 데이터 파일을 주목합니다. 이 제출은 September 16, 2025Thierry Piéton, 부사장 겸 최고재무책임자에 의해 서명되었습니다.

통지는 인수계약의 존재 여부와 날짜를 식별하지만, 거래 규모, 조건 또는 예상 자금 사용은 공개하지 않습니다.

Medtronic plc a déposé un 8-K divulguant un accord de souscription daté du 15 septembre 2025 entre Medtronic, Inc., Medtronic plc et Medtronic Global Holdings S.C.A., avec Deutsche Bank AG, London Branch et Goldman Sachs & Co. LLC désignés comme représentants des souscripteurs. Le dossier indique également un fichier de données interactives de couverture intégré au document Inline XBRL. Le dépôt est signé le 16 septembre 2025 par Thierry Piéton, vice-président exécutif et directeur financier.

L'avis identifie l'existence et la date de l'accord de souscription et les souscripteurs principaux mais ne révèle ni la taille de la transaction, ni les termes, ni l'utilisation prévue des fonds.

Medtronic plc reichte eine 8-K ein, die ein Underwriting Agreement dated September 15, 2025 zwischen Medtronic, Inc., Medtronic plc und Medtronic Global Holdings S.C.A. umfasst, wobei Deutsche Bank AG, London Branch und Goldman Sachs & Co. LLC als Vertreterinnen der jeweiligen Underwriter benannt sind. Die Einreichung vermerkt auch eine eingebettete Cover Page Interactive Data File mit dem Inline XBRL-Dokument. Die Einreichung ist am September 16, 2025 von Thierry Piéton, Executive Vice President und Chief Financial Officer, signiert.

Die Mitteilung identifiziert die Existenz und das Datum der Underwriting-Vereinbarung und die Lead Underwriters, offenbart jedoch weder die Transaktionsgröße, die Bedingungen noch die beabsichtigte Verwendung der Erlöse.

Medtronic plc قدمت ملف 8-K يكشف عن اتفاقية الاكتتاب المؤرخة 15 سبتمبر 2025 بين Medtronic, Inc. وMedtronic plc وMedtronic Global Holdings S.C.A., مع Deutsche Bank AG, London Branch وGoldman Sachs & Co. LLC مذكورين كنواب للكتّاب المستقلين. كما يشير الملف إلى وجود ملف بيانات مدمج على صفحة الغلاف التفاعلية مع مستند Inline XBRL. وهذا التقديم مُوقّع في 16 سبتمبر 2025 من قبل Thierry Piéton، نائب الرئيس التنفيذي ومدير القسم المالي.

وتشير الإخطار إلى وجود وتاريخ ترتيب الاكتتاب والكتّاب الرئيسيين، لكنها لا تكشف عن حجم الصفقة أو الشروط أو الاستخدام المقصود لعائدات.

Medtronic plc 已提交一份8-K披露 2025年9月15日 的承销协议,该协议在 Medtronic, Inc.、Medtronic plc 与 Medtronic Global Holdings S.C.A. 之间,Deutsche Bank AG, London BranchGoldman Sachs & Co. LLC 被指定为各自承销商的代表。 filing 还提及嵌入式封面页面交互式数据文件及 Inline XBRL 文档。该提交于 2025年9月16日Thierry Piéton,执行副总裁兼首席财务官签署。

通知识别了承销安排的存在及日期以及主承销商,但未披露交易规模、条款或资金用途。

0001613103 H91 VY19 false 0001613103 2025-09-15 2025-09-15 0001613103 us-gaap:CommonStockMember 2025-09-15 2025-09-15 0001613103 mdt:A0.000SeniorNotesDue2025Member 2025-09-15 2025-09-15 0001613103 mdt:A2.625SeniorNotesDue2025Member 2025-09-15 2025-09-15 0001613103 mdt:A1.125SeniorNotesDue2027Member 2025-09-15 2025-09-15 0001613103 mdt:A0.375SeniorNotesDue2028Member 2025-09-15 2025-09-15 0001613103 mdt:A3.000SeniorNotesDue2028Member 2025-09-15 2025-09-15 0001613103 mdt:A3.650SeniorNotesDue2029Member 2025-09-15 2025-09-15 0001613103 mdt:A1.625SeniorNotesDue2031Member 2025-09-15 2025-09-15 0001613103 mdt:A1.000SeniorNotesDue2031Member 2025-09-15 2025-09-15 0001613103 mdt:A3.125SeniorNotesDue2031Member 2025-09-15 2025-09-15 0001613103 mdt:A0.750SeniorNotesDue2032Member 2025-09-15 2025-09-15 0001613103 mdt:A3.375SeniorNotesDue2034Member 2025-09-15 2025-09-15 0001613103 mdt:A3.875SeniorNotesDue2036Member 2025-09-15 2025-09-15 0001613103 mdt:A2.250SeniorNotesDue2039Member 2025-09-15 2025-09-15 0001613103 mdt:A1.500SeniorNotesDue2039Member 2025-09-15 2025-09-15 0001613103 mdt:A1.375SeniorNotesDue2040Member 2025-09-15 2025-09-15 0001613103 mdt:A4.150SeniorNotesDue2043Member 2025-09-15 2025-09-15 0001613103 mdt:A1.750SeniorNotesDue2049Member 2025-09-15 2025-09-15 0001613103 mdt:A1.625SeniorNotesDue2050Member 2025-09-15 2025-09-15 0001613103 mdt:A4.150SeniorNotesDue2053Member 2025-09-15 2025-09-15
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2025

 

 

Medtronic plc

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Ireland   1-36820   98-1183488

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

Building Two

Parkmore Business Park West

Galway, Ireland

(Address of principal executive offices)

+353 1 438-1700

(Registrant’s telephone number, including area code)

Not Applicable

Former name or former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol

 

Name of each exchange

on which registered

Ordinary shares, par value $0.0001 per share   MDT   New York Stock Exchange
0.000% Senior Notes due 2025   MDT/25A   New York Stock Exchange
2.625% Senior Notes due 2025   MDT/25B   New York Stock Exchange
1.125% Senior Notes due 2027   MDT/27   New York Stock Exchange
0.375% Senior Notes due 2028   MDT/28   New York Stock Exchange
3.000% Senior Notes due 2028   MDT/28A   New York Stock Exchange
3.650% Senior Notes due 2029   MDT/29   New York Stock Exchange
1.625% Senior Notes due 2031   MDT/31   New York Stock Exchange
1.000% Senior Notes due 2031   MDT/31A   New York Stock Exchange
3.125% Senior Notes due 2031   MDT/31B   New York Stock Exchange
0.750% Senior Notes due 2032   MDT/32   New York Stock Exchange
3.375% Senior Notes due 2034   MDT/34   New York Stock Exchange
3.875% Senior Notes due 2036   MDT/36   New York Stock Exchange
2.250% Senior Notes due 2039   MDT/39A   New York Stock Exchange
1.500% Senior Notes due 2039   MDT/39B   New York Stock Exchange
1.375% Senior Notes due 2040   MDT/40A   New York Stock Exchange
4.150% Senior Notes due 2043   MDT/43A   New York Stock Exchange
1.750% Senior Notes due 2049   MDT/49   New York Stock Exchange
1.625% Senior Notes due 2050   MDT/50   New York Stock Exchange
4.150% Senior Notes due 2053   MDT/53   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 7.01.

Regulation FD Disclosure.

On September 15, 2025, Medtronic public limited company (“Medtronic plc”) issued a press release announcing the pricing of the Offering (as defined below), the net proceeds of which are expected to be used to repay Medtronic Global Holdings S.C.A.’s (“Medtronic Luxco”) 0.000% Senior Notes due 2025 and Medtronic Luxco’s 2.625% Senior Notes due 2025. The financial impact from the Offering and the expected use of proceeds was reflected in Medtronic plc’s fiscal year 2026 adjusted earnings per share guidance that Medtronic plc reiterated on August 19, 2025.

 

Item 8.01.

Other Events.

Underwriting Agreement

On September 15, 2025, Medtronic, Inc., Medtronic plc and Medtronic Luxco entered into an underwriting agreement (the “Underwriting Agreement”) with the underwriters listed therein, for which Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC acted as representatives. Pursuant to the Underwriting Agreement, Medtronic, Inc., an indirect wholly owned subsidiary of Medtronic plc, will issue and sell €750,000,000 aggregate principal amount of its 2.950% Senior Notes due 2030 (the “2030 Notes”) and €750,000,000 aggregate principal amount of its 4.200% Senior Notes due 2045 (the “2045 Notes” and together with the 2030 Notes, the “Notes”) to the underwriters, in an underwritten offering (the “Offering”) pursuant to a registration statement on Form S-3 (the “Registration Statement”) (File No. 333-270272) filed with the Securities and Exchange Commission (the “Commission”) on March 3, 2023, and a preliminary prospectus supplement and prospectus supplement filed with the Commission related to the Offering. The Notes are fully and unconditionally guaranteed on a joint and several basis by Medtronic Luxco and Medtronic plc.


A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated by reference into the Registration Statement. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

Redemption of Existing Notes

On September 16, 2025, Medtronic Luxco elected to redeem all €500,000,000 of its outstanding 2.625% Senior Notes due 2025 (CUSIP Number: 58507L AX7) (the “Redemption Notes”), on September 29, 2025 (the “Redemption Date”). The Redemption Notes will be redeemed at a redemption price equal to 100% of the principal amount of the Redemption Notes to be redeemed, plus accrued and unpaid interest to, but not including, the Redemption Date. Medtronic Luxco’s obligation to redeem the Redemption Notes is conditioned upon the completion of the issuance and sale of the Notes on or before the Redemption Date (which Redemption Date could be delayed in Medtronic Luxco’s sole discretion if this condition is not satisfied pursuant to the terms of the indenture governing the Redemption Notes).

Medtronic Luxco has given notice to Computershare Trust Company, N.A., as the trustee (the “Trustee”) and U.S. Bank Europe DAC, as the paying agent (the “Paying Agent”), for the Redemption Notes, instructing the Paying Agent to distribute a notice of redemption to all registered holders of the Redemption Notes on September 17, 2025. Copies of such notice of redemption and additional information relating to the procedure for redemption of the Redemption Notes may be obtained from the Paying Agent.

The information contained in this Current Report on Form 8-K does not constitute a notice of redemption of the Redemption Notes. Holders of the Redemption Notes should refer to the notice of redemption to be delivered by the Paying Agent to the registered holders of the Redemption Notes.

 

Item 9.01.

Exhibits.

 

Exhibit
Number
  

Description

1.1    Underwriting Agreement, dated as of September 15, 2025, among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., and Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC as representatives of the several underwriters named therein.
104    Cover Page Interactive Data File (embedded with the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDTRONIC PUBLIC LIMITED COMPANY
    By  

/s/ Thierry Piéton

Date: September 16, 2025       Thierry Piéton
      Executive Vice President and Chief Financial Officer

FAQ

What did Medtronic (MDT) disclose in this 8-K?

The company disclosed an Underwriting Agreement dated September 15, 2025 naming Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC as representatives; the document is signed by the CFO on September 16, 2025.

Does the filing show the size or type of securities being offered by MDT?

No. The 8-K names the agreement and underwriters but does not disclose offering size, pricing, or the type of securities.

Who signed the 8-K for Medtronic and when?

Thierry Piéton, Executive Vice President and Chief Financial Officer, signed the filing on September 16, 2025.

Are the lead underwriters for the potential offering disclosed?

Yes. The representatives named are Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC.

What additional filings should investors expect after this 8-K?

Investors should expect a prospectus, prospectus supplement, or related SEC filing that discloses offering size, pricing, securities type, and use of proceeds.
Medtronic

NYSE:MDT

MDT Rankings

MDT Latest News

MDT Latest SEC Filings

MDT Stock Data

116.68B
1.28B
0.3%
87.24%
1.03%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
Ireland
GALWAY